Ren et al. [20] reported that PCED1B-AS1 accelerated GC progression via adsorbing miR-215-3p and up-regulating CXCR1, indicating that PCED1B-AS1 is a novel therapeutic target for treating GC. Here, PCED1B is linked to gastric cancer.